CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects

As February begins, major U.S. stock indexes have shown a robust start, with the Dow Jones Industrial Average and S&P 500 posting significant gains. In such an optimistic market climate, investors often look beyond the well-known giants to explore opportunities in lesser-known areas like penny stocks. Though traditionally associated with high risk, penny stocks can offer intriguing prospects when supported by solid financials. This article will highlight three such companies that may provide promising investment opportunities for those seeking growth potential in smaller or newer firms.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating Dingdong (Cayman) (DDL) $2.74 $685.78M ★★★★★★ Waterdrop (WDH) $1.78 $640.14M ★★★★★☆ LexinFintech Holdings (LX) $2.65 $455.99M ★★★★★★ CI&T (CINT) $4.86 $665.96M ★★★★★☆ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Cricut (CRCT) $4.475 $946.5M ★★★★★★ Nephros (NEPH) $3.88 $43.68M ★★★★★★ LifeVantage (LFVN) $4.65 $59.11M ★★★★★★ BAB (BABB) $0.96 $6.83M ★★★★★★ Lifetime Brands (LCUT) $3.23 $72.73M ★★★★★☆

Click here to see the full list of 345 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

CytoMed Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company developing novel cell-based immunotherapies for treating human cancers and degenerative diseases in Malaysia and Singapore, with a market cap of $9.81 million.

Operations: CytoMed Therapeutics Limited has not reported any revenue segments.

Market Cap: $9.81M

CytoMed Therapeutics, a pre-revenue biopharmaceutical company with a market cap of US$9.81 million, is actively developing novel cell-based immunotherapies. Despite its unprofitability and high volatility compared to most US stocks, the company has made significant strides in clinical trials for cancer treatments using its proprietary T cell technologies. Recent collaborations include a Phase I trial with Universiti Malaya Medical Centre and research with MD Anderson Cancer Center, highlighting potential breakthroughs in treating acute myeloid leukemia. While challenges remain due to limited revenue and short cash runway, these strategic initiatives position CytoMed as an innovative contender in the biotech sector.

Click here to discover the nuances of CytoMed Therapeutics with our detailed analytical financial health report. Examine CytoMed Therapeutics' past performance report to understand how it has performed in prior years.GDTC Financial Position Analysis as at Feb 2026

Tandy Leather Factory

Simply Wall St Financial Health Rating: ★★★★★★

Story Continues

Overview: Tandy Leather Factory, Inc. operates as a retailer of leather and leathercraft-related products in the United States, Canada, and Spain, with a market cap of $25.57 million.

Operations: The company generates revenue from its Apparel segment, which amounted to $74.55 million.

Market Cap: $25.57M

Tandy Leather Factory, Inc., with a market cap of US$25.57 million, recently declared a special cash dividend of $0.75 per share, payable in February 2026. Despite a net loss of US$1.35 million for Q3 2025, the company reported significant profit growth over the past year with earnings increasing by 326.2%, surpassing industry averages and improving its net profit margin to 13.9%. The company's strong financial position is underscored by no debt and short-term assets exceeding liabilities significantly, though it faces challenges with an inexperienced board and low return on equity at 19.4%.

Navigate through the intricacies of Tandy Leather Factory with our comprehensive balance sheet health report here. Gain insights into Tandy Leather Factory's past trends and performance with our report on the company's historical track record.TLF Financial Position Analysis as at Feb 2026

Investview

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Investview, Inc. operates as a financial technology services company both in the United States and internationally, with a market cap of $55.24 million.

Operations: The company generates revenue from its operations internationally with $30.2 million and within the United States with $10.8 million.

Market Cap: $55.24M

Investview, Inc., with a market cap of US$55.24 million, faces challenges as it navigates regulatory scrutiny and financial volatility. Recent enforcement actions by Polish authorities against its iGenius operations could impact its business model and financial health if appeals are unsuccessful. Despite being unprofitable, the company has improved its financial position over five years by reducing losses at a significant rate and maintaining more cash than total debt. Its board is experienced, with recent additions like Robert Verdun potentially strengthening governance. The company's stock buyback initiative reflects confidence but highlights ongoing operational adjustments amid international pressures.

Dive into the specifics of Investview here with our thorough balance sheet health report. Evaluate Investview's historical performance by accessing our past performance report.INVU Debt to Equity History and Analysis as at Feb 2026

Summing It All Up

Click through to start exploring the rest of the 342 US Penny Stocks now. Curious About Other Options? Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GDTCTLF and INVU.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments